Men with organ-confined prostate cancer (CaP) are often treated with radical prostatectomy. Despite similar postoperative characteristics, a significant proportion of men with an intermediate risk of progression experience prostate-specific antigen (PSA)-defined failure, while others have relapse-free survival (RFS). Additional prognostic markers are needed to predict the outcome of these patients. KLLN is a transcription factor that regulates the cell cycle and induces apoptosis in cancer cells. We have shown that KLLN is an androgenregulated gene and that loss of KLLN expression in primary CaP is associated with high Gleason score. In this retrospective study, we evaluated KLLN expression in the high-grade malignancy components from 109 men with intermediate risk CaP. Patients with nuclear KLLN-negative tumors had significantly higher preoperative serum PSA levels (12.24G 2.37 ng/ml) and larger tumor volumes (4.61G0.71 cm 3 ) compared with nuclear KLLN-positive patients (8.35G2.45 ng/ml, PZ0.03, and 2.66G0.51 cm 3 , P!0.0001, respectively). None of the nuclear KLLN-positive tumors had capsular penetration, whereas 34% of nuclear KLLNnegative tumors (PZ0.004) had capsular penetration. Maintaining KLLN expression in tumor nuclei, but not in cytoplasm or stroma, associated with improved RFS after surgery (PZ0.002). Only 7% of patients with nuclear KLLN-positive tumors had tumor recurrence, while 60% of patients in the KLLN-negative group developed PSA-defined failure with median relapse time of 6.6 months (PZ0.0003). Our data suggest that KLLN expression may be used as a prognostic marker to predict outcome for intermediate risk patients, which could provide useful information for postoperative management.
Introduction risk prostate cancer (IRPC) (D'Amico et al. 1998a , DeSantis et al. 2013 . According to risk classification, the intermediaterisk group includes those with stage T2b-T2c tumors, PSA between 10 and 20 ng/ml, or Gleason score 7 (D' Amico et al. 1998b) . After radical prostatectomy (RP), 65-80% of patients with IRPC had 5-year relapse-free survival (RFS) (D'Amico et al. 1998b ,c,d, Meng et al. 2005 , Park et al. 2005 . In contrast, other IRPC patients with similar tumor characteristics have PSA-defined failure and metastasis after the same initial treatment, which uniformly lead to cancer-specific death. Currently, it remains a challenge to accurately predict oncologic outcomes for IRPC patients, especially for those with high Gleason grade lesions. Therefore, a reliable preoperative biomarker is urgently needed, which not only provides aggressive therapy for patients who will have recurrent tumor, but also prevents overtreatment in patients who do not relapse.
KLLN (KILLIN) is a newly identified gene located in 10q23.31 (Cho & Liang 2008) . KLLN and tumor suppressor phosphatase and tensin homolog (PTEN) share the same promoter regions but are transcribed in the opposite direction (Cho & Liang 2008 , Bennett et al. 2011 . KLLN is a DNA-binding protein that regulates cell cycle and apoptosis in diverse types of cancer cells (Cho & Liang 2008 , Wang et al. 2013a . Our previous studies have shown that KLLN functions as a tumor suppressor and transcription factor mainly localized to the cell nucleus (Wang et al. 2013a,b) . In CaP cell lines, KLLN and androgen receptor (AR) negatively regulate each other at the transcriptional levels, resulting in a negative feedback loop (Wang et al. 2013b) . Overexpression of KLLN suppresses AR expression and decreases PSA levels in CaP cells (Wang et al. 2013b) . We have also shown that loss of KLLN expression in CaP associates with high Gleason score, suggesting that KLLN might be used as a potential prognostic marker for risk management (Wang et al. 2013b) . In this study, we sought to analyze KLLN expression as a marker to predict clinical outcomes in patients with intermediate Gleason score CaP.
Materials and methods

Patients and human tissues
Paraffin-embedded RP specimens were collected at Stanford University Hospital. Consent had been obtained from each patient after full explanation of the purpose and nature of all procedures. 
Immunohistochemistry and quantification
Tissue sections were cut at 5 mm, deparaffinized in xylene, and rehydrated in a series of graded ethanol. Antigen retrieval was carried out with 0.01 M citrate buffer at pH 6.0 for 20 min in a 121 8C pressure chamber. The slides were allowed to cool for another 30 min, followed by sequential rinsing in PBS-T (0.01% Triton-X). Endogenous peroxidase activity was quenched by incubating in PBS-T containing 5% hydrogen peroxide. Each incubation step was carried out at room temperature and was followed by three sequential washes in PBS-T. The sections were incubated in rabbit polyclonal anti-KLLN antibody (Abgent, San Diego, CA, USA) at dilution of 1:100 in PBS-T containing 5% goat serum albumin, followed by incubations with biotinylated secondary antibody for 1 h, peroxidase-labeled streptavidin (Vectastain system, Vector, Burlingame, CA, USA) for 1 h, and diaminobenzidine-substrate for peroxidase-based immunohistochemistry (Cardassian DAB Chromogen, Biocare Medical, Concord, CA, USA). The slides were counterstained with hematoxylin (Vector) and mounted. W Y and two pathologists, A R and F A-K, independently evaluated the KLLN staining in Gleason grade 4 and 5 malignancies, blinded to outcomes. Positive KLLN staining in tumor cell nucleus, tumor cell cytoplasm, and adjacent stromal cells were recorded. The loss of KLLN expression in nucleus, cytoplasm, or stroma was defined by negative staining in all cells at the prospective locations.
Statistical analyses
SVI, capsular penetration, positive SM, and KLLN expression between two groups were compared using the c 2 test. The differences in PSA levels, tumor volumes, prostate weight, and follow-up time between two groups were evaluated using unpaired t-test. Spearman's rank correlation coefficient was used to analyze pairwise correlation between patient characteristics. Variables associated with tumor recurrence were analyzed by univariate and multivariate logistic regression. PSAdefined failure was defined as the PSA nadir C2 ng/ml according to the Phoenix criteria. RFSs were calculated to the event using the Kaplan-Meier method. Statistical analyses were performed using Prism version 6.0 (GraphPad Software, La Jolla, CA, USA) and SPSS statistical software package version 13.0 (SPSS, Inc.).
Results
Patient characteristics
This series had patients with a median age of 64G6.1 years, median preoperative serum PSA level of 8.7G 11.28 ng/ml and median follow-up of 2069 days (Table 1 ). The median tumor volume was 3.3G3.4 cm 3 .
SVI presented in 26/109 (23.9%) patients and 21/109 (19.3%) patients had positive SM (Table 1 ). There were 33/109 (30%) patient samples with capsular penetration (Table 1) . Among these 109 patients, 50 (45.9%) had RFS with the median 2251G161 days of follow-up while 59 (54.1%) experienced PSA-defined failure (Table 1) . For patients with recurrent disease, the median time to relapse was 198G55 days (Table 1) .
PSA-defined recurrence associated with loss of nuclear KLLN expression, SVI, and capsular penetration
We first compared clinical and pathologic characteristics of patients with RFS (nZ50) and those with PSA-defined failure (nZ59). Both epithelial and stromal KLLN expressions were detected in Gleason grade 4 and/or 5 lesions (Fig. 1 ). We found 76% of patients with RFS lost nuclear KLLN expression compared with 98% in patients who experienced recurrent disease (PZ0.0003) ( Table 2 ). In contrast, cancers from the relapse-free group and recurrence group did not show any significant difference in cytoplasmic (PZ0.079) or stromal KLLN expression (PZ0.36) ( Table 2 ). The median prostate weight was similar in the relapse-free (43.00G5.00 g) and recurrence groups (43.00G4.62 g, PZ0.99). The recurrence group had slightly higher preoperative PSA levels (12.65G2.09 ng/ml) and larger index tumor volume (4.70G0.94 cm 3 ) compared with the relapse-free group (10.75G3.91 ng/ml and 4.0G 0.84 cm 3 respectively), but the differences were not significant (PZ0.39 and PZ0.29 respectively) ( Table 2 ). In the recurrence group, 36% had SVI compared with 10% in the relapse-free group (PZ0.002) ( Table 2 ). The tumors in the recurrence group also displayed more capsular penetration (51%) and positive SM (31%), compared with tumors from the relapse-free group (6%, P!0.0001 and 6%, PZ0.0012 respectively) ( Table 2 ). Among the eight morphologic variables in our study, loss of nuclear KLLN (Table 3 ). Spearman's rank correlation analysis showed that these three factors are not correlated, suggesting nuclear-KLLN expression lost as an independent risk factor in association with RP prognosis for tumor recurrences (Supplementary Table S1 , see section on supplementary data given at the end of this article).
Positive nuclear KLLN expression in CaP associates with good prognosis after RP
We then compared clinical and pathological characteristics in patients with nuclear KLLN-positive tumors and those who lost KLLN expression in tumor nuclei.
Nuclear KLLN expression was detected in 13/109 (12%) patients (Table 4) . We noticed that all nuclear KLLNpositive patients express KLLN in the tumor cytoplasm as well. Patients in this nuclear KLLN-positive group had significantly lower preoperative PSA levels (8.35G 2.45 ng/ml) compared with those of the nuclear KLLNnegative group (12.24G2.37 ng/ml, PZ0.031) ( Table 4 ). In addition, tumor volume in nuclear KLLN-positive patients (2.66G0.51 cm 3 ) was significantly smaller compared with that in the nuclear KLLN-negative group (4.61G0.71 cm 3 , P!0.0001) ( Table 4) . Patients in nuclear KLLN-positive groups have less SVI and positive SM, but the differences are not significant (PZ0.15 and 0.06 respectively) ( Table 4) . Of 96 nuclear KLLN-negative tumors, 34% had capsular penetration, which was not observed in any of the nuclear KLLN-positive tumors (PZ0.011) ( Table 4) . Most importantly, only 7% of nuclear KLLN-positive patients had PSA-defined recurrence compared with 60% of patients with nuclear KLLN-negative cancers, who had median relapse time of 6.6 months (PZ0.0003) ( Table 4) . Kaplan-Meier plots show that nuclear KLLN-positive patients have significantly improved RFS compared with that of the KLLN-negative group during the average 6.1 years of follow-up (PZ0.002) ( Fig. 2A) . Patients maintaining only cytoplasmic KLLN expression did not show an improved RFS compared with cytoplasmic KLLN-negative patients (PZ0.25) (Fig. 2B) . In summary, our data suggest that maintaining nuclear KLLN expression in high Gleason score tumors might associate with improved RFS in IRPC patients. (Fig. 3A) . Deletions of KLLN significantly associated with decreased KLLN mRNA expression levels in those tumors (P!0.0001) (Fig. 3A) .
KLLN deletion associates with PTEN deletion in IRPC
PTEN deletion was commonly found in advanced CaP. As (Fig. 3B) . Decreased KLLN copy number significantly associated with loss of PTEN in IRPC (Spearman rZ0.91, P!0.0001) (Fig. 3C ). In addition, the expression of KLLN and PTEN is also associated with IRPC (Fig. 3D ). Our analysis shows the high frequency of deletion of both PTEN and KLLN in IRPC, which in turn associates with decrease in both genes' RNA expression.
Discussion
KLLN was first identified as a p53-targeted DNA-binding protein regulating cell cycle and apoptosis in monkey kidney cells (Cho & Liang 2008) . Our previous study revealed that KLLN is a transcription factor and mainly functions in the cell nucleus (Wang et al. 2013a,b) . CaP patients have significantly decreased KLLN expression in the tumor compared with adjacent normal tissue (Wang et al. 2013b) . Loss of KLLN expression may be an early event during tumor development and is associated with high Gleason score in CaP (Wang et al. 2013b) . In CaP cells, KLLN inhibits AR expression by transcriptional suppression, resulting in decreased PSA levels (Wang et al. 2013b) . This function aligns with our current finding that patients with nuclear KLLN-negative tumors have higher preoperative PSA levels, although of course secretion of PSA from normal prostate glands as well as benign prostatic hyperplasia (BPH) contributes to serum PSA levels. In our current cohort, patients with nuclear KLLN-negative tumors have higher prevalence of SVI, positive SM, and capsular penetration. However, Spearman's r indicates that nuclear KLLN expression is an independent risk factor for predicting patients' surgical outcome. Patients with grade 4 or 5 malignancies have poorer prognosis than the men with 100% grade 3 prostate tumors. However, the proportion of grade 4/5 tumors does not distinguish the surgical outcome. Our current study shows that risk of PSA-defined relapse was increased 24-fold in men with nuclear KLLN-negative high-grade tumors, compared with men with nuclear KLLN expression (Table 3 ). It appears that KLLN expression in the tumor cytoplasm and stroma did not associate with patient pre-or postoperative characteristics or surgical outcome. This suggests that loss of nuclear KLLN expression in neoplasias might play important roles in tumor progression and contribute to tumor aggressiveness. In IRPC patients, preoperation biopsies often only contain grade 3 lesions even though grades 4 or 5 can be observed in the PR specimens. Further validation of our findings in biopsies will provide more evidence for using KLLN as preoperative marker to predictive patient outcome and to personalize postsurgical cancer management. Genomic deletions of PTEN in CaP have been shown to confer an unfavorable clinical outcome , most likely through decreased PTEN expression and subsequent upregulation of the AKT signaling pathway (Canby-Hagino et al. 2005 , Wang et al. 2010 , Costello et al. 2011 . Hemizygous and homozygous PTEN deletions were found in 40% of locally advanced CaP and the incidence of PTEN deletion in CRPC may reach 70-80% (Swanson et al. 2006a ,b,c, Ramahi et al. 2012 . A recent study has shown that, in CaP, the most frequent loss at 10q23 including the PTEN ranges from 36 kb to 90 Mb in size (Yoshimoto et al. 2012) . Considering the fact that KLLN lies in proximity to PTEN in 10q23 and shares a bidirectional promoter with PTEN, such deletions of PTEN in CaP may also include KLLN, which may explain the loss of KLLN expression in CaP. Our study revealed that 90% IRPC tumor samples with homozygous PTEN deletions also have KLLN deletions, indicating that genome insatiability may affect both tumor suppressors simultaneously. As PTEN deletion is commonly found in many types of cancers, it is highly possible that loss of KLLN may play a novel role in the development and progression of other cancer types as well. We have already shown that KLLN expression negatively correlated with AR expression in an independent cohort of CaP from 183 patients (Wang et al. 2013b) . AR directly suppresses KLLN transcription in CaP cell lines (Wang et al. 2013b) . Therefore, it is also possible that the increased AR activity in advanced CaP results in decreased KLLN expression levels. CaP risk drives treatment selection, whereas accurate prediction of surgical outcome for each individual is extremely challenging. A reliable predictive marker for prolonged RFS or PSA failure would be essential for patient cancer management after their surgeries. It could guide the clinician to offer aggressive treatment to patients who are potentially at higher risk. Importantly, it can also prevent overtreatment for high-risk patients who actually have long-term RFS without further intervention. Several previous studies have developed preoperative scoring systems to predict a patient's earlier probability of tumor recurrence (Kattan et al. 1998 , San Francisco et al. 2004 , Cooperberg et al. 2006 , Stephenson et al. 2006 . The strength of the current study is the utilization of a single marker to predict the oncologic outcomes for patients with IRPC. To minimize bias and clinical heterogeneity, all our study patients had tumors of the same Gleason score and no one received neoadjuvant therapy before RP or adjuvant treatment after RP. We found that patients with nuclear KLLN expression in primary tumors had a high likelihood of long-term RFS despite the presence of high Gleason grade malignancies. In the nuclear KLLN-positive group, only 7% of the patients experienced PSA failure. In contrast, 60% of patients who lost nuclear KLLN expression had tumor recurrences, with median relapse time of 6.6 months. Our data also showed that nuclear KLLN expression in primary tumors associates with lower preoperative PSA levels, smaller tumor size, and fewer positive margins. They also suggest that patients with different KLLN expression patterns, regarding subcellular localization, should have different postsurgical cancer management. One limitation in current study is the selection of high-grade tumor lesions, in which majority of cell nuclei are KLLN-negative. Our follow-up study will investigate the association between KLLN expression in Gleason grade 3 tumors and patient surgical outcome.
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